Acute Kidney Injury Genomics and Biomarkers in TAVR Study
AI Description
In the last decade, transcatheter aortic valve replacement (TAVR) has become an increasingly utilized alternative procedure for replacing a stenotic aortic valve. This study collects clinical information, DNA, blood and urine samples (throughout procedural hospitalization) in order to investigate the incidence of acute kidney injury (AKI) in patients undergoing TAVR and to identify key clinical and procedural predictors of AKI. This study seeks to identify blood and urine biomarkers that can be used for early detection of AKI around the time of the procedure. The study seeks to assess for novel genetic variants associated with development of AKI after TAVR. Finally the study seeks to assess for novel genetic variants and biomarkers that are associated with adverse cardiovascular events after TAVR and to further explore how these events may inter-relate with acute kidney injury.
- Who can join
- adult, older adult
- Participants
- 62
- Expected completion
- 2031-03-31
- Funded by
- other
Conditions studied
Acute Kidney Injury, Arrhythmias, Cardiac, Heart Failure, Myocardial Infarction, Renal Insufficiency, Chronic, Stroke
What is being tested
- PROCEDURE: Transcatheter Aortic Valve Replacement
What it measures
- Acute Kidney Injury using KDIGO criteria, Data will be collected from electronic medical records; data points to be collected for this measurement include serum creatinine, Day of procedure to post procedure day 5
Centers Participating
These centers are participating in this study. Reach out to them directly to learn more.
Registry entry updated 2025-07-29
Deciding whether to join a study is your choice, and you can ask a study team questions before you decide anything.
If you would rather we did it with you, call us on (656) 206-4686.